Olmesartan: sprue-like enteropathyPrescrire international (Paris). 2014, Vol 23, Num 148, issn 1167-7422, p. 102Article

Risk of hepatotoxicity associated with fluoroquinolones: A national case―control safety studyALSHAMMARI, Thamir M; LARRAT, E. Paul; MORRILL, Haley J et al.American journal of health-system pharmacy. 2014, Vol 71, Num 1, pp 37-43, issn 1079-2082, 7 p.Article

Dabigatran: ulcérations digestivesLa Revue Prescrire. 2014, Vol 34, Num 365, issn 0247-7750, p. 197Article

Prise en charge des nausées et vomissements chimio-induits: une expérience monocentrique de terrain = Prevention and treatment of chemotherapy-induced nausea and vomiting: a real-life monocentric experienceLECOQ, Anne-Lise; BAZIN, Christophe; CLERE, Nicolas et al.Journal de pharmacie clinique (Paris). 2014, Vol 33, Num 2, pp 91-99, issn 0291-1981, 9 p.Article

Methodology to Assess Clinical Liver Safety DataMERZ, Michael; LEE, Kwan R; KULLAK-UBLICK, Gerd A et al.Drug safety. 2014, Vol 37, issn 0114-5916, S33-S45, SUP1Article

An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomitingFABI, Alessandra; MALAGUTI, Paola.Expert opinion on pharmacotherapy. 2013, Vol 14, Num 5, pp 629-641, issn 1465-6566, 13 p.Article

Asymptomatic elevation of liver enzymes due to levetiracetam: a case reportSETHI, Nitin K; SETHI, Prahlad K; TORGOVNICK, Josh et al.Drug metabolism and drug interactions. 2013, Vol 28, Num 2, pp 123-124, issn 0792-5077, 2 p.Article

Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory PerspectivesSHAH, Rashmi R; MORGANROTH, Joel; SHAH, Devron R et al.Drug safety. 2013, Vol 36, Num 7, pp 491-503, issn 0114-5916, 13 p.Article

Entéropathie sévère avec atrophie villositaire associée à la prise d'olmésartan médoxomil = Severe Enteropathy with Villous Atrophy Olmesartan Medoxomil-associatedNUNGE, Débora; EOCHE, Matthieu; FUMERY, Mathurin et al.Thérapie (Paris). 2013, Vol 68, Num 6, pp 419-421, issn 0040-5957, 3 p.Article

Proton pump inhibitors: Clostridium difficile infectionsPrescrire international (Paris). 2013, Vol 22, Num 142, pp 239-240, issn 1167-7422, 2 p.Article

Management of NSAID/Aspirin-Induced Small Intestinal Damage by GI-Sparing NSAIDs, Anti-Ulcer Drugs and Food Constituents : Novel Physiological and Pharmacological Avenues in the Mechanism of Gastrointestinal Integrity, Protection and Ulcer HealingSATOH, H; TAKEUCHI, K.Current medicinal chemistry. 2012, Vol 19, Num 1, pp 82-89, issn 0929-8673, 8 p.Article

Opioid-Induced Bowel Dysfunction: Pathophysiology and ManagementBROCK, Christina; SCHOU OLESEN, Søren; ESTRUP OLESEN, Anne et al.Drugs (Basel). 2012, Vol 72, Num 14, pp 1847-1865, issn 0012-6667, 19 p.Article

Current Challenges and Controversies in Drug-Induced Liver InjuryCORSINI, Alberto; GANEY, Patricia; SUTER, Laura et al.Drug safety. 2012, Vol 35, Num 12, pp 1099-1117, issn 0114-5916, 19 p.Article

True storyLESAGE, X; MARIETTE, C; MAUNOURY, V et al.La Lettre de l'hépato-gastroentérologue. 2011, Vol 14, Num 2, issn 1286-580X, p. 86Article

Second-generation antipsychotics and constipation: A review of the literatureDE HERT, M; HUDYANA, H; DOCKX, L et al.European psychiatry. 2011, Vol 26, Num 1, pp 34-44, issn 0924-9338, 11 p.Article

Failure of liver function tests in predicting drug clearance of chlemotherapeutic agents in a patient who had recovered from hepatic congestionTSUBOKURA, Masaharu; MIURA, Yuji; KAMI, Masahiro et al.British journal of clinical pharmacology. 2010, Vol 70, Num 2, pp 277-279, issn 0306-5251, 3 p.Article

Atteinte hépatique secondaire à la prise d'un phyto-médicament à base d'isoflavones de soja = Liver Injury from Phytotherapy Treatment Containing Soy IsoflavonesPHILIBERT, Christelle; SAFIA EL MESSAOUI; GIGNOUX, Matjeka et al.Thérapie (Paris). 2010, Vol 65, Num 5, pp 501-503, issn 0040-5957, 3 p.Article

Unintended Hepatic Adverse Events Associated with Cancer ChemotherapySENIOR, John R.Toxicologic pathology. 2010, Vol 38, Num 1, pp 142-147, issn 0192-6233, 6 p.Article

PRISE D'ACIDE ACÉTYLSALICYLIQUE À FAIBLE DOSE EN COMPRIMÉ ENTÉRIQUE ET ENTÉROPATHIE GRÊLE DISTALE: À PROPOS D'UN CAS ET REVUE DE LA LITTÉRATUREDE FELICIS, D; DUBOIS, A; NAKAD, A et al.Louvain médical. 2009, Vol 128, Num 7, pp 255-263, issn 0024-6956, 9 p.Article

Hepatic Effects of Lovastatin Exposure in Patients with Liver Disease : A Retrospective Cohort StudyAVINS, Andrew L; MANOS, Michele M; ACKERSON, Lynn et al.Drug safety. 2008, Vol 31, Num 4, pp 325-334, issn 0114-5916, 10 p.Article

Peroxisome Proliferator-Activated Receptor-β/δ Protects Against Chemically Induced Liver Toxicity in MiceWEIWEI SHAN; NICOL, Christopher J; ITO, Shinji et al.Hepatology (Baltimore, Md.). 2008, Vol 47, Num 1, pp 225-235, issn 0270-9139, 11 p.Article

Effect of 5-HT₂ receptor blockade on cadmium-induced acute toxicityTZIROGIANNIS, Konstantinos N; DEMONAKOU, Maria D; PAPADIMAS, George K et al.Digestive diseases and sciences. 2007, Vol 52, Num 9, pp 2351-2358, issn 0163-2116, 8 p.Article

Etiology of new-onset jaundice : How often is it caused by idiosyncratic drug-induced liver injury in the United States?VUPPALANCHI, Raj; LIANGPUNSAKUL, Suthat; CHALASANI, Naga et al.The American journal of gastroenterology. 2007, Vol 102, Num 3, pp 558-562, issn 0002-9270, 5 p.Article

Global gastrointestinal safety profile of etoricoxib and lumiracoxib : COX-2 inhibition in gastroenterology and rheumatology: current challenges and perspectives for the futureYUHONG YUAN; HUNT, Richard H.Current pharmaceutical design. 2007, Vol 13, Num 22, pp 2237-2247, issn 1381-6128, 11 p.Article

Rivastigmine et rupture de l'oesophage (suite) = Rivastigmine and oesophagus ruptureLa Revue Prescrire. 2007, Vol 27, Num 282, pp 268-268, issn 0247-7750, 1 p.Article